IDH1 and central nervous system cancer: The metabolic hallmark of this glioma subtype is the high level of the oncometabolite 2-hydroxyglutarate (2-HG) by the mutant IDH1 enzyme via the NADPH-dependent reduction of α-ketoglutarate.